GenMont Biotech Announcement of Shareholders' Meeting Resolution to Permit Directors to Engage in Competitive Business
GenMont Biotech's shareholders' meeting resolved to permit directors to engage in competitive business, including Chairman Chen Gen-de and six others to hold concurrent positions in subsidiaries or other companies for a period from June 30, 2026 to June 29, 2029.
📋 Article Processing Timeline
- 📰 Published: June 8, 2026 at 09:00
- 🔍 Collected: June 9, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: June 12, 2026 at 12:43 (76h 43m after Collected)
1. Date of shareholders' meeting: 115/06/08
2. Names and titles of directors permitted to engage in competitive business:
(1) Chen Gen-de, Chairman.
(2) Huang Guo-jie, Director.
(3) Yang Zhuo-hui, Director.
(4) Zhuo Chuan-zhen, Director.
(5) Li Xiang-zhou, Director.
(6) Lin Qing-long, Independent Director.
(7) Chen Shi-kun, Independent Director.
3. Items of permitted competitive business:
(1) Chen Gen-de concurrently serves as Chairman of the subsidiary GenMont Biotech (China) Co., Ltd.
(2) Huang Guo-jie concurrently serves as Director of the subsidiary GenMont Biotech (China) Co., Ltd., and CEO of Youjun Construction Engineering Co., Ltd.
(3) Yang Zhuo-hui concurrently serves as Director of the subsidiary GenMont Biotech (China) Co., Ltd.
(4) Zhuo Chuan-zhen concurrently serves as Supervisor of the subsidiary GenMont Biotech (China) Co., Ltd., and Senior Partner at ShineWing United Certified Public Accountants.
(5) Li Xiang-zhou concurrently serves as Advisor to He Song Technology Co., Ltd. and Zhang Jing Development Co., Ltd.
(6) Chen Shi-kun concurrently serves as Supervisor of Juli Construction Co., Ltd., and Chairman of Changfeng Investment Co., Ltd.
(7) Lin Qing-long concurrently serves as Director of Qinglong United Certified Public Accountants, Chairman of Qinglong Business Enterprise Co., Ltd., Chairman of Kingston Business Co., Ltd., and Chairman of Wanzhan Inn Hotel Co., Ltd.
4. Period of permitted competitive business: from June 30, 2026 to June 29, 2029.
5. Resolution situation (explain voting results according to Article 209 of the Company Act): Passed after voting.
6. If the permitted competitive business involves operations in mainland China, the director's name and title (if not, enter "Not applicable"): Chen Gen-de Chairman, Huang Guo-jie Director, Yang Zhuo-hui Director, Zhuo Chuan-zhen Director.
7. The company name and position of the mainland China business:
Chen Gen-de, Chairman of GenMont Biotech (China) Co., Ltd.
Huang Guo-jie, Director of GenMont Biotech (China) Co., Ltd.
Yang Zhuo-hui, Director of GenMont Biotech (China) Co., Ltd.
Zhuo Chuan-zhen, Supervisor of GenMont Biotech (China) Co., Ltd.
8. Address of the mainland China business: No. 19 Guangyuan Road, Wuqing Development Zone, Tianjin
9. Business items of the mainland China business: Biotechnology promotion; production and sales of food, beverages, feed additives; wholesale, retail, import and export of the above products.
10. Degree of impact on the company's financial business: As it is a subsidiary 85% owned by the company, it has no significant impact on the company.
11. If the director has invested in the mainland China business, the investment amount and shareholding ratio: None.
12. Other matters to be stated: None.
2. Names and titles of directors permitted to engage in competitive business:
(1) Chen Gen-de, Chairman.
(2) Huang Guo-jie, Director.
(3) Yang Zhuo-hui, Director.
(4) Zhuo Chuan-zhen, Director.
(5) Li Xiang-zhou, Director.
(6) Lin Qing-long, Independent Director.
(7) Chen Shi-kun, Independent Director.
3. Items of permitted competitive business:
(1) Chen Gen-de concurrently serves as Chairman of the subsidiary GenMont Biotech (China) Co., Ltd.
(2) Huang Guo-jie concurrently serves as Director of the subsidiary GenMont Biotech (China) Co., Ltd., and CEO of Youjun Construction Engineering Co., Ltd.
(3) Yang Zhuo-hui concurrently serves as Director of the subsidiary GenMont Biotech (China) Co., Ltd.
(4) Zhuo Chuan-zhen concurrently serves as Supervisor of the subsidiary GenMont Biotech (China) Co., Ltd., and Senior Partner at ShineWing United Certified Public Accountants.
(5) Li Xiang-zhou concurrently serves as Advisor to He Song Technology Co., Ltd. and Zhang Jing Development Co., Ltd.
(6) Chen Shi-kun concurrently serves as Supervisor of Juli Construction Co., Ltd., and Chairman of Changfeng Investment Co., Ltd.
(7) Lin Qing-long concurrently serves as Director of Qinglong United Certified Public Accountants, Chairman of Qinglong Business Enterprise Co., Ltd., Chairman of Kingston Business Co., Ltd., and Chairman of Wanzhan Inn Hotel Co., Ltd.
4. Period of permitted competitive business: from June 30, 2026 to June 29, 2029.
5. Resolution situation (explain voting results according to Article 209 of the Company Act): Passed after voting.
6. If the permitted competitive business involves operations in mainland China, the director's name and title (if not, enter "Not applicable"): Chen Gen-de Chairman, Huang Guo-jie Director, Yang Zhuo-hui Director, Zhuo Chuan-zhen Director.
7. The company name and position of the mainland China business:
Chen Gen-de, Chairman of GenMont Biotech (China) Co., Ltd.
Huang Guo-jie, Director of GenMont Biotech (China) Co., Ltd.
Yang Zhuo-hui, Director of GenMont Biotech (China) Co., Ltd.
Zhuo Chuan-zhen, Supervisor of GenMont Biotech (China) Co., Ltd.
8. Address of the mainland China business: No. 19 Guangyuan Road, Wuqing Development Zone, Tianjin
9. Business items of the mainland China business: Biotechnology promotion; production and sales of food, beverages, feed additives; wholesale, retail, import and export of the above products.
10. Degree of impact on the company's financial business: As it is a subsidiary 85% owned by the company, it has no significant impact on the company.
11. If the director has invested in the mainland China business, the investment amount and shareholding ratio: None.
12. Other matters to be stated: None.
FAQ
When was this resolution passed?
At the shareholders' meeting on June 8, 2026.
How long is the permission period?
From June 30, 2026 to June 29, 2029, three years.
Where is the China subsidiary located?
No. 19 Guangyuan Road, Wuqing Development Zone, Tianjin.